Evidence map›Paper›PMID 33673529›Full record

SynthesisViruses2021

Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review.

Apparao Peddapalli, Manish Gehani, Arunasree M Kalle, Siva R Peddapalli, Angela E Peter, Shashwat Sharad

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. COVID-19 induced shocks and its implications for human capital development.International journal for equity in health · 2024
    Article
  5. Severe COVID-19European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  6. Review
  7. Review
  8. Stem cell therapy for COVID-19 pneumonia.Molecular biomedicine · 2022
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

Apparao PeddapalliDepartment of Microbiology, King George Hospital, Visakhapatnam 531011, Andhra Pradesh, India.
Manish GehaniDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani-Hyderabad Campus, Hyderabad 500078, Telangana, India.ORCID 0000-0002-5894-4106
Arunasree M KalleDepartment of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad 500046, Telangana, India.
Siva R PeddapalliDepartment of Biological Sciences-Biotechnology, Florida Institute of Technology, Melbourne, FL 32901, USA.ORCID 0000-0002-5090-5751
Angela E PeterDepartment of Biotechnology, College of Science & Technology, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India.ORCID 0000-0002-6198-7211
Shashwat SharadCenter for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20817, USA.
Andhra University · INBirla Institute of Technology and Science - Hyderabad Campus · INFlorida Institute of Technology · USHenry M. Jackson Foundation · USKing George Hospital · INUniversity of Hyderabad · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunological findings from autopsies, biopsies, and various studies in COVID-19 patients show that the major cause of morbidity and mortality in COVID-19 is excess immune response resulting in hyper-inflammation. With the objective to review various mechanisms of excess immune response in adult COVID-19 patients, Pubmed was searched for free full articles not related to therapeutics or co-morbid sub-groups, published in English until 27.10.2020, irrespective of type of article, country, or region. Joanna Briggs Institute's design-specific checklists were used to assess the risk of bias. Out of 122 records screened for eligibility, 42 articles were included in the final review. The review found that eventually, most mechanisms result in cytokine excess and up-regulation of Nuclear Factor-κB (NF-κB) signaling as a common pathway of excess immune response. Molecules blocking NF-κB or targeting downstream effectors like Tumour Necrosis Factor α (TNFα) are either undergoing clinical trials or lack specificity and cause unwanted side effects. Neutralization of upstream histamine by histamine-conjugated normal human immunoglobulin has been demonstrated to inhibit the nuclear translocation of NF-κB, thereby preventing the release of pro-inflammatory cytokines Interleukin (IL) 1β, TNF-α, and IL-6 and IL-10 in a safer manner. The authors recommend repositioning it in COVID-19.

Indexed as

COVID-19Cytokine Release SyndromeDatabases, FactualDown-RegulationDrug RepositioningHistamineHumansImmunityImmunoglobulinsNF-kappa BOrphan Drug ProductionSARS-CoV-2Signal TransductionHistamineImmunoglobulinsNF-kappa BCOVID-19cytokine stormexcess immune responsehistamine-conjugated-normal human immunoglobulinhyper-inflammationrepositioningSARS-CoV-2

Identifiers

PMID33673529
PMCPMC7997247
OpenAlexW3135433485

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.